A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects

BACKGROUND: Complications of bone metastases such as skeletal-related events lead to the impaired functional status and quality of life including death in patients with bone metastasis from solid tumors. Denosumab (XGEVA®) is indicated for the prevention of skeletal-related events in bone metastasis...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Yanhua, Liu, Yusi, Dou, Changlin, Guo, Shuren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494459/
https://www.ncbi.nlm.nih.gov/pubmed/37701913
http://dx.doi.org/10.1016/j.jbo.2023.100499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494459/
https://www.ncbi.nlm.nih.gov/pubmed/37701913
http://dx.doi.org/10.1016/j.jbo.2023.100499

Ejemplares similares